Supriya Lifescience Share Price Target 2026 Analyst Forecast Bull and Bear Case
- June 24, 2026
- Posted by: Neeraj Pandey
- Category: News
The Supriya Lifescience share price target 2026 is Rs 1,150, implying approximately 20 percent upside from the current market price of Rs 960.85 (NSE: SUPRIYA). With Q4 FY26 results released in 2026 and Pharmaceutical APIs and Contract Research tailwinds in focus, the Rs 1,150 price objective is supported by the FY27 earnings recovery thesis.
Supriya Lifescience (NSE: SUPRIYA) is a Pharmaceutical APIs and Contract Research company trading at Rs 960.85 with a market capitalisation of Rs 2,884 crore. Analysts have set the Supriya Lifescience share price target at Rs 1,150 for 2026, based on FY27 earnings projections and sector re-rating potential. This article covers the complete 2026 price forecast including sector tailwinds, key risks, and bull and bear scenarios.
Click Here – Get Free Investment Predictions
Supriya Lifescience Share Price Target 2026: Key Takeaways
- Supriya Lifescience share price target 2026: Rs 1,150 (20% upside from CMP Rs 960.85)
- Bull case: Rs 1,400 | Bear case: Rs 770
- Ticker: SUPRIYA | Sector: Pharmaceutical APIs and Contract Research | MCap: Rs 2,884 crore
- 52W range: Rs 666 to Rs 1,576 | PE: 25x
- Key catalyst: Q4 FY26 results and FY27 earnings confirmation in 2026
- Key risk: FY27 earnings miss or FII outflows from Indian equities
Supriya Lifescience Company Overview
Supriya Lifescience (NSE: SUPRIYA) is a Mumbai-based pharmaceutical API and CRAMS company manufacturing specialty APIs for antihistamines, analgesics, and anaesthetics for regulated US, EU, and Japanese markets, with FY26 revenue of Rs 650 crore. At CMP Rs 960.85 against a 52 week range of Rs 666 to Rs 1,576, the stock trades at a meaningful discount to its 52 week high. Market capitalisation is Rs 2,884 crore with trailing PE of 25x. Compared to peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences, Supriya Lifescience is positioned as a potential re-rating candidate toward the Rs 1,150 price objective on FY27 earnings delivery.
| Parameter | Value |
|---|---|
| NSE Ticker | SUPRIYA |
| Sector | Pharmaceutical APIs and Contract Research |
| CMP (2026) | Rs 960.85 |
| 52 Week High | Rs 1,576 |
| 52 Week Low | Rs 666 |
| Market Cap | Rs 2,884 crore |
| Trailing PE | 25x |
| 12-Month Analyst Target | Rs 1,150 |
| Bull Case Target | Rs 1,400 |
| Bear Case Target | Rs 770 |
Why Is the Supriya Lifescience Share Price Target Set at Rs 1,150 for 2026
FY27 Earnings Recovery and Revenue Acceleration
The Supriya Lifescience share price target of Rs 1,150 rests on analyst projections of 15 to 20 percent PAT growth in FY27. Q4 FY26 results released in 2026 confirming the earnings trajectory are the most direct catalyst for re-rating from CMP Rs 960.85.
Structural Sector Tailwinds in Pharmaceutical APIs and Contract Research
The Pharmaceutical APIs and Contract Research sector is expanding on the back of India’s domestic demand growth, PLI scheme support, and rising corporate investment. Supriya Lifescience’s position among peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences creates a structural growth runway. Sustained outperformance is one of the key conditions for the Rs 1,400 bull case to materialise.
RBI Rate Cut Cycle and Lower Cost of Capital
India’s RBI rate cut cycle in 2026 is reducing borrowing costs and stimulating end market demand. Lower interest costs improve Supriya Lifescience’s EPS trajectory, narrowing the gap between current earnings and the FY27 estimates that underpin the Rs 1,150 analyst consensus.
Union Budget 2026-27 Capex Push and Policy Support
Budget 2026-27’s Rs 11.21 lakh crore infrastructure capex and PLI scheme continuity create a favourable backdrop for Supriya Lifescience’s Pharmaceutical APIs and Contract Research operations, improving the probability of achieving the Rs 1,150 price objective through FY27 earnings delivery.
FII Flow Normalisation After the 2026 Tariff Shock
As global macro conditions normalise through 2026, FII flows into quality Indian equities are gradually recovering. At 25x PE, Supriya Lifescience is positioned as a beneficiary of institutional reallocation toward the Rs 1,400 bull case over the medium term.
Supriya Lifescience Share Price Targets: Short Term, 12 Month, and Long Term
Short Term Supriya Lifescience Share Price Target
Near-term support for Supriya Lifescience is anchored close to the 52 week low of Rs 666. A confirmed Q4 FY26 earnings recovery in 2026 is the trigger for an initial 10 to 15 percent re-rating from CMP Rs 960.85.
12-Month Supriya Lifescience Share Price Target 2026
The 12-month Supriya Lifescience share price target 2026 is Rs 1,150, implying approximately 20 percent upside from CMP Rs 960.85. This base case assumes in-line FY27 earnings delivery and partial normalisation of FII flows.
Long Term Supriya Lifescience Share Price Target: FY27 to FY28
The long term Supriya Lifescience share price target for FY27 to FY28 is Rs 1,400 in the bull case, requiring full earnings delivery, re-rating among peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences, and sustained institutional buying over a 2 to 3 year horizon.
Bull Case and Bear Case Scenarios for Supriya Lifescience in 2026
Bull Case Supriya Lifescience Share Price Target: Rs 1,400
The bull case Supriya Lifescience share price target of Rs 1,400 materialises when FY27 earnings beat analyst estimates, Pharmaceutical APIs and Contract Research tailwinds accelerate, and FII flows return strongly to Indian equities. From CMP Rs 960.85, this represents approximately 45 percent potential upside.
Bear Case Supriya Lifescience Share Price Target: Rs 770
The bear case Supriya Lifescience share price target of Rs 770 materialises if FY27 earnings disappoint or FII outflows depress the broader market, risking a test of support near the 52 week low of Rs 666.
| Scenario | Target | Key Conditions |
|---|---|---|
| Bull Case | Rs 1,400 | FY27 beat, sector re-rating, FII inflows |
| Base Case (Analyst Target) | Rs 1,150 | In-line FY27 delivery, partial FII recovery |
| Bear Case | Rs 770 | FY27 miss, guidance cut, FII outflows persist |
Key Risks That Could Derail the Supriya Lifescience 2026 Price Objective
Global Macro and US Tariff Headwinds
Prolonged tariff tensions and global demand slowdown remain prominent macro risks to the Supriya Lifescience share price target of Rs 1,150, with FII outflows being the direct transmission mechanism to Indian equity valuations.
FY27 Earnings Miss and Guidance Risk
An FY27 earnings miss or downward guidance revision would compress valuation multiples and is the most direct company-specific risk to the Rs 1,150 analyst price objective. Investors must monitor quarterly results and management commentary closely.
Competitive Intensity Among Pharmaceutical APIs and Contract Research Peers
Intensifying competition from peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences could compress Supriya Lifescience’s market share and pricing power, a structural risk that must be weighed when assessing the defensibility of the earnings trajectory underpinning the Rs 1,150 analyst target for 2026.
Liquidity Risk and FII Selling Pressure
Sustained FII outflows from Indian equities can delay the re-rating process regardless of company-level improvement. Investors should maintain position sizing discipline and stop losses to protect capital.
How to Invest in Supriya Lifescience
Check the Univest Screener for live data
Before considering any investment based on the Supriya Lifescience share price target of Rs 1,150, review Q4 FY26 results and FY27 guidance released in 2026. Focus on revenue growth, margin trends, and management commentary on Pharmaceutical APIs and Contract Research sector demand.
Open a Demat account with a SEBI registered stockbroker to trade Supriya Lifescience (NSE: SUPRIYA) with full regulatory protection. Study the competitive landscape among peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences before executing any position.
Plan your entry using the 52 week low of Rs 666 as a key support reference. A confirmed FY27 earnings uptick validates the entry case for the Rs 1,150 price objective. Always set a stop loss below the 52 week low.
Restrict any single stock to 3 to 5 percent of your total equity portfolio. Always consult a SEBI registered financial advisor before investing. SEBI Registration No. INH000013776.
Download the Univest iOS App or the Univest Android App to track Supriya Lifescience’s live share price and receive daily stock recommendations.
Disclaimer Note: The securities quoted, if any, are for illustration only and are not recommendatory. This content is for educational purposes only and does not constitute investment advice. Investments in securities are subject to market risk. Read all related documents carefully before investing. SEBI Registration No. INH000013776.
FAQs on Supriya Lifescience Share Price Target 2026
What is the Supriya Lifescience share price target for 2026?
Ans. The Supriya Lifescience share price target 2026 is Rs 1,150, implying approximately 20 percent upside from CMP Rs 960.85. Bull case is Rs 1,400, bear case is Rs 770.
What was the Supriya Lifescience share price target for 2025?
Ans. The 2025 price objective for Supriya Lifescience was based on FY26 earnings projections. The current 2026 analyst consensus is Rs 1,150, reflecting FY27 growth potential from CMP Rs 960.85.
Is Supriya Lifescience a good investment at Rs 960.85?
Ans. At Rs 960.85, Supriya Lifescience offers potential upside toward Rs 1,150 if FY27 earnings recover. Whether this represents a good entry depends on individual risk tolerance. Consult a SEBI registered financial advisor before investing.
What are the key risks to the Supriya Lifescience share price target 2026?
Ans. Key risks to the Supriya Lifescience share price target of Rs 1,150 include FY27 earnings miss, global tariff headwinds, FII outflows, and competitive pressure in Pharmaceutical APIs and Contract Research. Monitoring quarterly results is essential.
What is the 52 week high and low of Supriya Lifescience?
Ans. The 52 week high of Supriya Lifescience is Rs 1,576 and the 52 week low is Rs 666. At CMP Rs 960.85, the stock offers potential upside toward the Rs 1,150 price objective.
What are the main growth catalysts for Supriya Lifescience in 2026?
Ans. Key catalysts include FY27 PAT recovery, Pharmaceutical APIs and Contract Research tailwinds, RBI rate cuts in 2026, Budget 2026-27 policy support, and normalisation of FII flows into Indian equities.
How does Supriya Lifescience compare to its peers?
Ans. Supriya Lifescience operates in Pharmaceutical APIs and Contract Research alongside peers in pharma APIs like Divi’s Laboratories and Suven Life Sciences. At CMP Rs 960.85 with MCap Rs 2,884 crore, it is a potential re-rating candidate toward the Supriya Lifescience share price target of Rs 1,150 on FY27 delivery.
What is the Supriya Lifescience share price target for 2027?
Ans. The long-term Supriya Lifescience share price target for FY27 to FY28 is Rs 1,400 in the bull case, assuming earnings growth, sector re-rating, and FII inflows. Consult a SEBI registered financial advisor for personalised guidance.
